The first profitable quarter in two years rests on licensing: a $613 million recognition on the Bristol Myers Squibb pumitamig deal carried the beat. Track the oncology launch timeline rather than the headline numbers.
Latest Activity
Bristol Myers Squibb cut full-year adjusted EPS guidance to $6.35 to $6.55 from $6.75 to $7.00 even though both lines topped expectations, a split driven by acquired IPRD charges while the revenue outlook went up. Keep an eye on the stock as investors weigh the dealmaking hit.
Defense and big pharma own the top of the board at the open, led by Northrop Grumman up 5.36%, with Eli Lilly, Bristol-Myers Squibb and Merck also higher. The pain is concentrated in crypto miners and optics names, where IREN leads the decline.
Every one of today's five worst performers in a 383-name universe lost double digits, led by CoreWeave's 15.42% drop. The best gain on the other side was capped at 4.62%, so the downside is moving far faster than the upside.
A 4.10% intraday move to $58.90 adds roughly $5 billion to a $120 billion drugmaker, and big pharma rarely travels that far in a single session. Worth seeing whether the gain holds into the close.
A 4.29% slide to $57.23 is an outsized single session for a $117 billion pharma name that usually trades like a bond proxy. Dividend buyers watching for an entry get a cheaper one today.
Both Petrobras lines closed double digits higher, the only names in a 383-stock board to do it. MercadoLibre and Tempus AI each added more than 9%, while the worst loser gave up under 5%, so the upside skew was lopsided.
BMY Coverage
Conagra Cut Its Dividend 50%. The Stock Market Was Warning Investors
Conagra's falling stock price told one story while its board told another, and the board lost. Four more high-yield payers are sending the same mixed signals, and one cash flow line shows…
3 Defensive Dividend Stocks for Retirees Worried About the Next Market Downturn
Phone plans, cancer drugs, and pipeline tolls keep getting paid when the economy stalls. Three low-beta dividend payers each carry one risk that could undercut the income, and only one of them…
4 Healthcare Dividend Stocks for Retirees. One Yields Over 4%
A fat starting yield can hide thin raises, while the slowest payers boast decades of increases. Four low-volatility healthcare blue chips force retirees to choose between income today and income that grows,…
How to Use the Years Between 62 and 75 to Turn a $1.05 Million IRA Into $5,100 a Month Tax-Free
When the paychecks stop at 62 and Social Security can wait, a short stretch of near-zero income opens a tax window most retirees never notice. Miss it, and the IRS decides how…
A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer
A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they…
Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year
Pharmacy counters stay busy in every kind of market. Blood thinners, cancer drugs, and vaccines get refilled on schedule, and the companies that make them return part of those sales to shareholders…
$200,000 in Dividend Stocks: How a Roth IRA Could Save You $2,166 a Year
Six famous high-yield stocks pay the same income wherever you hold them, yet two of them quietly trigger most of the tax bill. Find out which two, and why the account you…
5 Defensive Dividend Stocks Yielding Up to 8.7% for Retirement Income
Recessions punish shaky payouts, but some companies keep collecting cash anyway. From power lines to pipelines to pill bottles, five low-beta names promise income, yet one of them runs coverage tighter than…
Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?
A blockbuster blood thinner is about to lose $1.5 billion to $2 billion in sales, and the debt pile hasn't gone away. Retirees counting on Bristol Myers Squibb's payout need to know…
AbbVie Hit a New High After Earnings. There’s More Upside Left.
AbbVie just logged a 33% gain for the year and raised its guidance again, but the real question is whether Skyrizi and a newly closed pipeline deal can push shares even further…
Pfizer Yields Nearly 6%, but Its Dividend Exceeds Free Cash Flow. Is It Safe?
Pfizer's dividend yield sits near 6%, but the company paid out more in dividends last year than it generated in free cash flow. Before income investors panic or pile in, the real…
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher
Merck (NYSE:MRK | MRK Price Prediction) is the second big drugmaker to reward investors with an earnings beat and a raised profit outlook. However, Merck’s steady, Keytruda-anchored growth tells a very different…
3 Blue-Chip Dividend Stocks That Show Why Roth IRA Income Can Be Worth More
Where you hold a dividend stock matters almost as much as which one you pick, and three blue-chip payers reveal exactly how much the IRS quietly collects each year depending on your…
Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%
Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) push into cancer treatment is drawing heavy buying as a closely followed melanoma presentation approaches. Shares of Moderna are up 7% to $241.89 during the trading…
Pfizer’s Dividend Freeze Raises a Bigger Question About Its Cash Flow
Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash generation. The math behind that payout is more uncomfortable than the headline…